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In the original article \[[@CR1]\], we mentioned that some study characteristics of the article by Dagan and colleagues \[2\] were unavailable. However, we realized that the authors provided the relevant information in their supplementary file. As such, we added participant characteristics (i.e., age = 68.8 ± 6.8, gender = 17 M, 3 F, PD duration = 9.0 ± 5.7, and UPDRS Part III at baseline = Total 39.7 ± 14.6) to Table [1](#Tab1){ref-type="table"}, stimulation parameters (i.e., intensity = 3 mA, duration = 20 min, areas = 3 cm^2^) to Table [2](#Tab2){ref-type="table"}, and methodological quality assessments (i.e., allocation concealment = 1 and Total score = 9) to Table [3](#Tab3){ref-type="table"}. Based on the new information, we updated Fig. [2](#Fig1){ref-type="fig"} with the corrected selection bias and performance bias results. Finally, we confirmed that these corrections did not change the meta-analytic findings in the original article. Table 1Participant characteristicsStudyTotal NAge (yrs)GenderPD Duration (yrs)UPDRS Part III at BaselineMedicationDBS TreatmentFOG TestAlizad \[42\]8NATotal: 3F, 5 MNANANANONABenninger \[43\]25Total: 63.9 ± 8.7Active: 4F, 9 MSham: 5F, 7 MActive: 10.6 ± 7.1Sham: 9.1 ± 3.3Active: 22.2 ± 8.7Sham: 17.5 ± 8.0OnNOPatients with severe freezing or unable to walk 10 m were excludedCapacci \[44\]7Total: 60.9 ± 9Total: 4F, 3 MTotal: 16.8 ± 4.0NANANONACosta-Ribeiro \[45\]22Active: 61.1 ± 9.1;Sham: 62.0 ± 16.7Active: 3F, 8 MSham: 4F, 7 MActive: 6.1 ± 3.8Sham: 6.3 ± 3.7Active: 19.0Sham: 19.1OnNOFOG-Q(\> 15 points) were excludedCosta-Ribeiro \[46\]22Active: 61.1 ± 9.1Sham: 62.0 ± 16.7Active: 3F, 8 MSham: 4F, 7 MActive: 6.1 ± 3.8Sham: 6.3 ± 3.7Active: 19.0 ± 4.9Sham: 17.6 ± 5.1OnNOPatients were excluded when they presented severe freezing according the FOG-QCriminger \[47\]16Total: 68.1 ± 9.8Total: 4F, 12 MTotal: 8.7 ± 9.8Total: 23.4 ± 9.7OnNONAda Silva \[48\]17Active: 66.0 ± 5.0Sham: 66.0 ± 10.0Active: 4F, 4 MSham: 3F, 6 MActive: 6.0 ± 6.0Sham: 5.0 ± 1.0NANANONADagan \[49\]20Total: 68.8 ± 6.8Total: 17 M, 3 FTotal: 9.0 ± 5.7Total: 39.7 ± 14.6OnNOFOG-Q: 20.5 ± 4.9FOG-provoking test scores: 14.2 ± 8.00Fernández-Lago \[50\]18Total: 56.7 ± 11.6Total: 7F, 11 MTotal: 6.2 ± 3.7Total: 21.17 ± 11.3OnNONAKaski \[51\]16NANANANAOnNOPatients with severe freezing were excludedLattari \[52\]17Total: 67.2 ± 10.0Total: 4F, 13 MTotal: 7.1 ± 2.7Total: 18.0 ± 99.0OnNONAMak \[53\]18NANANANANANONAManenti \[54\]10Total: 67.1 ± 7.2Total: 4F, 6 MTotal: 8.1 ± 3.5Total: 13.3 ± 5.7OnNONASchabrun \[55\]16Active: 72.0 ± 4.9Sham: 63.0 ± 11.0Active: 8 MSham: 6F, 2 MActive: 6.9 ± 4.4Sham: 4.6 ± 3.9Active: 47.7 ± 7.5Sham: 37.7 ± 9.8OnNONASwank \[56\]10Total: 68.7 ± 10.2Total: 2F, 8 MTotal: 7.9 ± 7.1Total: 37.0 ± 12.9OnNONAValentino \[57\]10Total: 72.3 ± 3.6Total: 5F, 5 MTotal: 11.0 ± 4.9Total: 32.0 ± 10.3OnNOFOG-Q: 15.3 ± 2.7Verheyden \[58\]20NANATotal: 9.0 ± 4.0Total: 16.0 ± 5.0OnNONAYotnuengnit \[59\]53Active: 68.2 ± 9.8Sham: 62.7 ± 8.8Active: 6F, 11 MSham: 6F, 12 MActive: 9.4 ± 5.3Sham: 6.6 ± 3.6Active: 11.9 ± 4.7Sham: 11.2 ± 4.0OnNONA*Note*: Data for age and PD duration are mean ± standard deviation*Abbreviations*: *Active* active tDCS protocols, *DBS* deep brain stimulation, *F* female, *FOG* Freezing of gait, *FOG-Q* Freezing of gait questionnaire, *M* male, *NA* not applicable, *PD Duration* time since PD diagnosis, *UPDRS* the Unified Parkinson's Disease Rating Scale Table 2tDCS protocolsStudyTreatmentSession \#Active tDCSStimulation SiteStimulation Parameters\
(Intensity, Duration, Areas)Follow-Up TestAlizad \[42\]tDCS3AM: Bi PMC & M11 mA, 20 min, 40 cm^2^NoBenninger \[43\]tDCS8AM: Bi PFC, PMC, & M1 (separately)2 mA, 20 min, 24.5 cm^2^Yes (12wks)Capacci \[44\]tDCS1AM: Bi PFC (separately)2 mA, 20 min, NANoCosta-Ribeiro \[45\]tDCS&GT10AS: Central leg areas M1 (2 cm anterior to the vertex)2 mA, 13 min, NAYes (4wks)Costa-Ribeiro \[46\]tDCS&GT10AS: Central leg areas M1 (2 cm anterior to the vertex)2 mA, 13 min, 35 cm^2^Yes (4wks)Criminger \[47\]tDCS3A&CM: Bi DLPFC (A-tDCS on LH & C-tDCS on RH)2 mA, 20 min, 15 cm^2^Noda Silva \[48\]tDCS1AS: Central leg areas M1 & SMA2 mA, 15 min, 35 cm^2^NoDagan \[49\]tDCS2AM: M1 & LH-DLPFC3 mA, 20 min, 3 cm^2^NoFernández-Lago \[50\]tDCS&TT1AS: leg area M1 of AH2 mA, 20 min, 3.5 cm^2^NoKaski \[51\]tDCS&PT1AS: Central leg areas M1 (10--20% anterior to the vertex)2 mA, 15 min, 40 cm^2^NoLattari \[52\]tDCS1AS: LH DLPFC2 mA, 20 min, 35 cm^2^NoMak \[53\]tDCS5AS: M1NA, 20 min, NANoManenti \[54\]tDCS2AS: RH DLPFC2 mA, 7 min, 35 cm^2^NoSchabrun \[55\]tDCS&GT9AS: LH M12 mA, 20 min, 35 cm^2^Yes (12wks)Swank \[56\]tDCS1A&CM: Bi DLPFC (A-tDCS on LH & C-tDCS on RH)2 mA, 20 min, NANoValentino \[57\]tDCS5AS: Central leg areas M12 mA, 20 min, NAYes (4wks)Verheyden \[58\]tDCS1AS: LH M11 mA, 15 min, NANoYotnuengnit \[59\]tDCS&PT6AS: Central leg areas M12 mA, 30 min, 35 cm^2^Yes (8wks)*Abbreviations*: *A* anodal tDCS, *AH* affected hemisphere, *Bi* bilateral, *C* cathodal tDCS, *DLPFC* dorsolateral prefrontal cortex, *GT* gait training, *LH* left hemisphere, *M* multiple targeted brain regions, *M1* primary motor cortex, *NA* not applicable, *PFC* prefrontal cortex, *PMC* premotor cortex, *PT* physical training, *RH* right hemisphere, *S* single targeted brain region, *TT* treadmill training, *wks* weeks (retention period) Table. 3PEDro score for methodological quality assessmentItemsAlizad\
\[42\]Benninger\
\[43\]Capacci\
\[44\]Costa-Ribeiro\
\[45\]Costa-Ribeiro\
\[46\]Criminger\
\[47\]da Silva\
\[48\]Dagan\
\[49\]Fernandez-Lago\
\[50\]Kaski\
\[51\]Lattari\
\[52\]Mak\
\[53\]Manenti\
\[54\]Schabrun\
\[55\]Swank\
\[56\]Valentino\
\[57\]Verheyden\
\[58\]Yotnuengnit\
\[59\]1. Specific eligibility criteria0101111111101111112. Subjects random allocation1111111111110111013. Allocation concealment0111101101100100014. Similar groups at baseline0100000000111100015. Blinding of all subjects0101111101101111116. Blinding of all therapists0000100000000000007. Blinding of all assessors (at least one key outcome)0101101101101101118. Data measurement from more than 85% of the subjects initially allocated to groups (at least one key outcome)1111111111111111119. All subjects received the treatment or control condition as allocated (at least one key outcome)11111111111111111110. Between-group comparisons (at least one key outcome)01010111111110011011. Point measures and measures of variability (at least one key outcome)111111111110111111Total41059979969105896879 Fig. 2Cochrane risk of bias assessment. **a** Risk of bias summary and **b** Risk of bias graph
